Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rapid Administration of Carnitine in sEpsis (RACE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by University of Mississippi Medical Center
Information provided by (Responsible Party):
Alan Jones, University of Mississippi Medical Center Identifier:
First received: August 11, 2012
Last updated: July 3, 2014
Last verified: July 2014

Prior work has shown that exogenous L-carnitine administration enhances glucose and lactate oxidation, attenuates fatty acid toxicity, and improves endothelial-smooth muscle coupling and cardiac mechanical efficiency. The overall goal of this proposal is to investigate L-carnitine as a novel adjunctive treatment of septic shock. In this study the investigators will test our primary hypothesis: Early adjunctive L-carnitine administration in vasopressor dependent septic shock will significantly reduce cumulative organ failure at 48 hours with an associated decrease in 28-day mortality suggesting the need for further phase III study. To accomplish this the investigators will conduct a phase II, double blinded, placebo controlled, adaptive randomized trial of 250 eligible patients with vasopressor-dependent septic shock. Study subjects will be assigned to one of four arms: low (6g), medium (12g) or high (18g) dose intravenous L-carnitine or placebo for 12 hours as a part of early resuscitative care.

Condition Intervention Phase
Septic Shock
Drug: Levo-Carnitine
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Levo-Carnitine for Vasopressor Dependent Septic Shock

Resource links provided by NLM:

Further study details as provided by University of Mississippi Medical Center:

Primary Outcome Measures:
  • delta SOFA [ Time Frame: 48 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mortality [ Time Frame: 28 day ] [ Designated as safety issue: No ]

Estimated Enrollment: 250
Study Start Date: January 2013
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Control
Normal saline
Drug: placebo
Experimental: Carnitine Low
Levo-Carnitine 6g
Drug: Levo-Carnitine
Experimental: Carnitine Medium
Levo-Carnitine 12 g
Drug: Levo-Carnitine
Experimental: Carnitine High
Levo-Carnitine 18 g
Drug: Levo-Carnitine


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Suspected or confirmed infection (examples include but are not limited to: white cells in a normally sterile body fluid; perforated viscus; radiographic evidence of pneumonia in clinical symptoms; a syndrome associated with a high risk of infection e.g. cellulitis, cutaneous abscess, ascending cholangitis, toxic shock syndrome, fever of unknown origin with high suspicion of infectious etiology)
  2. Any two of four criteria of systemic inflammatory response as defined by the 2001 ACCP/SCCM Consensus Conference Committee;
  3. Recognition of septic shock and initiation of quantitative resuscitation within 24 hours of enrollment;
  4. Requirement of high dose vasopressors for ≥4 hours to treat shock: Norepinephrine > 0.05mcg/kg/min; dopamine >10mcg/kg/min; Phenylephrine >0.4 mcg/kg/min; epinephrine > 0.05 mcg/kg/min;
  5. Cumulative sequential organ failure assessment (SOFA) score of ≥ 6;
  6. Blood lactate level of >2.0 mMol/L.

Exclusion Criteria:

  1. Age <18 years;
  2. Pregnancy or breastfeeding;
  3. Any primary diagnosis other than sepsis;
  4. Established Do Not Resuscitate status or advanced directives restricting aggressive care or treating physician deems aggressive care unsuitable;
  5. Any history of seizures or a known seizure disorder;
  6. Any known inborn error of metabolism;
  7. Anticipated requirement for surgery that would interfere with the 12 hour infusion time;
  8. Active participation in another interventional study;
  9. Cardiopulmonary resuscitation (chest compression or defibrillation) prior to enrollment;
  10. Known systemic allergy to L-carnitine.
  11. Severe immunocompromised state (e.g. subject has neutropenia [receiving cytotoxic chemotherapy with absolute neutrophil count <500/uL or expected to decline to < 500 uL within the next three days).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01665092

Contact: Alan Jones, MD 601-984-5571

United States, Alabama
University of Alabama Birmingham Not yet recruiting
Birmingham, Alabama, United States
Contact: Henry Wang, MD         
Principal Investigator: Henry Wang, MD         
United States, California
Univeristy of California Davis Recruiting
Sacramento, California, United States
Contact: James Holmes, MD         
Principal Investigator: James Holmes, MD         
United States, Delaware
Christiana Care Health Services Recruiting
Wilmington, Delaware, United States
Contact: Ryan Aronold, MD         
Principal Investigator: Ryan Arnold, MD         
United States, Florida
University of Florida Recruiting
Jacksonville, Florida, United States
Contact: Faheem Gurgis, MD         
Principal Investigator: Faheem Gurgis, MD         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States
Contact: Mark Courtney, MD         
Principal Investigator: Mark Courtney, MD         
United States, Indiana
Indiana University Recruiting
Indianapolis, Indiana, United States
Contact: Jeffrey Kline, MD         
Principal Investigator: Jeffrey Kline, MD         
United States, Massachusetts
BIDMC Recruiting
Boston, Massachusetts, United States
Contact: Nathan Shapiro, MD         
Principal Investigator: Nathan Shapiro, MD         
United States, Michigan
Wayne State University Not yet recruiting
Detroit, Michigan, United States
Contact: Rob Sherwin, MD         
Principal Investigator: Rob Sherwin, MD         
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 29316
Contact: Alan Jones, MD    601-984-5443   
Principal Investigator: Alan Jones, MD         
United States, New Jersey
Cooper University Hospital Recruiting
Camden, New Jersey, United States
Contact: Stephen Trzeciak, MD         
Principal Investigator: Stephen Trzeciak, MD         
United States, North Carolina
Carolinas Medical Center Recruiting
Charlotte, North Carolina, United States
Contact: Mike Runyon, MD         
Principal Investigator: Mike Runyon, MD         
Sponsors and Collaborators
University of Mississippi Medical Center
Principal Investigator: Alan Jones, MD University of Mississippi Medical Center
  More Information

No publications provided

Responsible Party: Alan Jones, Professor of Emergency Medicine, University of Mississippi Medical Center Identifier: NCT01665092     History of Changes
Other Study ID Numbers: GM103799
Study First Received: August 11, 2012
Last Updated: July 3, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Vitamin B Complex
Vitamins processed this record on March 03, 2015